In a filing, Rapport Therapeutics Inc revealed its Director Huber Reid M acquired Company’s shares for reported $0.5 million on Sep 12 ’25. In the deal valued at $24.48 per share,20,400 shares were bought. As a result of this transaction, Huber Reid M now holds 20,400 shares worth roughly $0.53 million.
Then, PAUL STEVEN M bought 41,666 shares, generating $1,027,111 in total proceeds. Upon buying the shares at $24.65, the Director now owns 41,666 shares.
Before that, Young Wendy B. bought 3,500 shares. Rapport Therapeutics Inc shares valued at $79,100 were divested by the Director at a price of $22.60 per share. As a result of the transaction, Young Wendy B. now holds 9,500 shares, worth roughly $0.25 million.
Truist initiated its Rapport Therapeutics Inc [RAPP] rating to a Buy in a research note published on September 16, 2025; the price target was $44. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Citizens JMP began covering RAPP with “Mkt outperform” recommendation on April 08, 2025. TD Cowen started covering the stock on July 02, 2024. It rated RAPP as “a Buy”.
Price Performance Review of RAPP
On Tuesday, Rapport Therapeutics Inc [NASDAQ:RAPP] saw its stock jump 5.90% to $26.19. Over the last five days, the stock has lost -6.56%. Rapport Therapeutics Inc shares have risen nearly 38.50% since the year began. Nevertheless, the stocks have risen 47.63% over the past one year.
How much short interest is there in Rapport Therapeutics Inc?
A steep rise in short interest was recorded in Rapport Therapeutics Inc stocks on 2025-08-29, growing by 94809.0 shares to a total of 3.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 3.05 million shares. There was a rise of 3.01%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 02, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
